Last reviewed 2026-04-22 · How we verify

Secukinumab Auto-Injector

Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases.

Secukinumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated diseases. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.

At a glance

Mechanism of action

By binding to and neutralizing IL-17A, secukinumab inhibits the IL-17 signaling pathway, which plays a central role in the pathogenesis of autoimmune and inflammatory conditions. This reduces the recruitment and activation of immune cells at sites of inflammation, thereby suppressing the inflammatory cascade. The auto-injector formulation provides patients with a convenient subcutaneous delivery option.

Approved indications

• Moderate to severe plaque psoriasis
• Psoriatic arthritis
• Ankylosing spondylitis
• Non-radiographic axial spondyloarthritis

Common side effects

• Nasopharyngitis
• Upper respiratory tract infection
• Diarrhea
• Injection site reactions
• Candida infections

Key clinical trials

• Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV) (PHASE4)
• Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis (PHASE3)
• Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque Psoriasis (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.